Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections

被引:30
作者
Moellering, RC [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
关键词
D O I
10.1093/jac/44.suppl_1.25
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Vancomycin-resistant Enterococcus faecium (VREF) is an opportunistic pathogen, which causes infections among severely ill, hospitalized patients, in whom it is likely to increase the risk of progressive local or systemic disease and to worsen the prognosis. Because these organisms are often highly resistant to penicillin, ampicillin and many other antimicrobials including the glycopeptides, there are few proven therapeutic alternatives for the treatment of infection caused by VREF. Quinupristin/dalfopristin is highly active against VREF in vitro. A prolonged post-antibiotic effect, good polymorphonuclear leucocyte/macrophage penetration and slow release, and active metabolites allow this agent to be used with an 8 or 12 h dosing interval. The combined results from a Phase III non-comparative study and an emergency-use study of quinupristin/dalfopristin for the treatment of VREF infection produced a clinical response rate (cure or improvement) in 142 (73.6%) of 193 clinically evaluable patients. The baseline pathogen was eradicated or presumed eradicated from 110 of 156 (70.5%) bacteriologically evaluable patients. Fifty-two per cent of the severely ill patients in these two studies died, but no death was attributed to quinupristin/dalfopristin therapy. The most common adverse event was arthralgia (9.1%). Quinupristin/dalfopristin has demonstrated efficacy for the treatment of serious VREF infections, including those that have failed conventional therapy.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 36 条
[1]   Glycopeptide susceptibility among Danish Enterococcus faecium and Enterococcus faecalis isolates of animal and human origin and PCR identification of genes within the vanA cluster [J].
Aarestrup, FM ;
Ahrens, P ;
Madsen, M ;
Pallesen, LV ;
Poulsen, RL ;
Westh, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1938-1940
[2]   A critical evaluation of vancomycin for treatment of bacterial meningitis [J].
Ahmed, A .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (09) :895-903
[3]  
CDC, 1993, MMWR-MORBID MORTAL W, V42, P597
[4]   Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium [J].
Chia, JKS ;
Nakata, MM ;
Park, SS ;
Lewis, RP ;
McKee, B .
CLINICAL INFECTIOUS DISEASES, 1995, 21 (06) :1520-1520
[5]  
CRAIG W, 1993, 33 INT C ANT AG CHEM, P205
[6]   CELLULAR UPTAKE AND INTRACELLULAR BACTERICIDAL ACTIVITY OF RP 59500 IN MURINE MACROPHAGES [J].
DESNOTTES, JF ;
DIALLO, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :107-115
[7]  
deVera ME, 1996, ARCH SURG-CHICAGO, V131, P338
[8]  
Dowzicky Michael, 1998, American Journal of Medicine, V104, p34S, DOI 10.1016/S0002-9343(98)00153-3
[9]   Intracellular activities of RP 59500 (Quinupristin-Dalfopristin) and sparfloxacin against Enterococcus faecium [J].
HerreraInsua, I ;
JacquesPalaz, K ;
Murray, BE ;
Rakita, RM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :886-890
[10]  
*HOSP INF CONTR PR, 1995, MMWR-MORBID MORTAL W, V44, P1